APA (7th ed.) Citation

Hlobilková, A., Bouchal, J., Knillová, J., Strnad, M., & Kolář, Z. Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.

Chicago Style (17th ed.) Citation

Hlobilková, A., J. Bouchal, J. Knillová, M. Strnad, and Zdeněk Kolář. Synergic Effects of the Cyclin-dependent Kinase (CDK) Inhibitor Olomoucine and Androgen-antagonist Bicalutamide on Prostatic Cancer Cell Lines.

MLA (9th ed.) Citation

Hlobilková, A., et al. Synergic Effects of the Cyclin-dependent Kinase (CDK) Inhibitor Olomoucine and Androgen-antagonist Bicalutamide on Prostatic Cancer Cell Lines.